tiprankstipranks
NervGen Pharma (DE:9UA)
FRANKFURT:9UA
Germany Market
9UA
NervGen Pharma
RESEARCH TOOLSreports

NervGen Pharma (9UA) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

9UA Analyst Ratings

Strong Buy
4Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
Based on 4 analysts giving stock ratings to
NervGen
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

9UA Stock 12 Month Forecast

Average Price Target

€8.96
▲(548.98% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for NervGen Pharma in the last 3 months. The average price target is €8.96 with a high forecast of €13.00 and a low forecast of €5.20. The average price target represents a 548.98% change from the last price of €1.38.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","7":"€7","14":"€14","3.5":"€3.5","10.5":"€10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13.0004862,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€13.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.955890493333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€8.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.20019448,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€5.20</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.5,7,10.5,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.38,2.2738835538461535,3.167767107692307,4.0616506615384615,4.955534215384615,5.849417769230769,6.743301323076922,7.637184876923076,8.53106843076923,9.424951984615383,10.318835538461538,11.21271909230769,12.106602646153846,{"y":13.0004862,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.38,1.962760807179487,2.5455216143589743,3.1282824215384615,3.7110432287179487,4.293804035897436,4.876564843076923,5.45932565025641,6.0420864574358975,6.624847264615385,7.207608071794872,7.790368878974359,8.373129686153845,{"y":8.955890493333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.38,1.6738611138461539,1.9677222276923076,2.2615833415384614,2.5554444553846154,2.8493055692307694,3.143166683076923,3.437027796923077,3.730888910769231,4.0247500246153844,4.318611138461539,4.612472252307692,4.906333366153847,{"y":5.20019448,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.96,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.18,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.02,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.24,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.16,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€13.00Average Price Target€8.96Lowest Price Target€5.20
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:9UA
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
€15.6→€13
Buy
842.06%
Upside
Reiterated
07/14/26
NervGen Pharma price target lowered to $15 from $18 at H.C. WainwrightNervGen Pharma price target lowered to $15 from $18 at H.C. Wainwright
Leerink Partners Analyst forecast on DE:9UA
Marc Goodman
Leerink Partners
Leerink Partners
€8.67
Buy
528.04%
Upside
Initiated
07/13/26
NervGen Pharma initiated with an Outperform at LeerinkNervGen Pharma initiated with an Outperform at Leerink
TD Cowen Analyst forecast on DE:9UA
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Initiated
06/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stifel Nicolaus Analyst forecast on DE:9UA
Justin Keywood
Stifel Nicolaus
Stifel Nicolaus
€5.2
Buy
276.83%
Upside
Reiterated
05/21/26
NervGen Pharma (NGEN) Receives a Buy from Stifel Nicolaus
Lucid Capital Analyst forecast on DE:9UA
Elemer Piros
Lucid Capital
Lucid Capital
€15.6
Buy
1030.48%
Upside
Initiated
04/15/26
NervGen Pharma initiated with a Buy at Lucid CapitalNervGen Pharma initiated with a Buy at Lucid Capital
Research Capital Analyst forecast on DE:9UA
Andre Uddin
Research Capital
Research Capital
€4.77
Buy
245.42%
Upside
Reiterated
04/10/26
Is NervGenPharma still undervalued?Uddin said the pivotal study is expected to enroll about 150 patients at roughly 60 sites across the United States and Canada, with startup activity already underway and trial initiation still expected around mid-2026. He said enrollment could be completed in the second half of 2027, with topline data in the first half of 2028 and a potential NDA filing in the second half of 2028.
Maxim Group Analyst forecast on DE:9UA
Michael Okunewitch
Maxim Group
Maxim Group
€8.67→€10.4
Buy
653.65%
Upside
Assigned
04/09/26
NervGen Pharma price target raised to $12 from $10 at MaximNervGen Pharma price target raised to $12 from $10 at Maxim
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:9UA
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
€15.6→€13
Buy
842.06%
Upside
Reiterated
07/14/26
NervGen Pharma price target lowered to $15 from $18 at H.C. WainwrightNervGen Pharma price target lowered to $15 from $18 at H.C. Wainwright
Leerink Partners Analyst forecast on DE:9UA
Marc Goodman
Leerink Partners
Leerink Partners
€8.67
Buy
528.04%
Upside
Initiated
07/13/26
NervGen Pharma initiated with an Outperform at LeerinkNervGen Pharma initiated with an Outperform at Leerink
TD Cowen Analyst forecast on DE:9UA
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Initiated
06/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stifel Nicolaus Analyst forecast on DE:9UA
Justin Keywood
Stifel Nicolaus
Stifel Nicolaus
€5.2
Buy
276.83%
Upside
Reiterated
05/21/26
NervGen Pharma (NGEN) Receives a Buy from Stifel Nicolaus
Lucid Capital Analyst forecast on DE:9UA
Elemer Piros
Lucid Capital
Lucid Capital
€15.6
Buy
1030.48%
Upside
Initiated
04/15/26
NervGen Pharma initiated with a Buy at Lucid CapitalNervGen Pharma initiated with a Buy at Lucid Capital
Research Capital Analyst forecast on DE:9UA
Andre Uddin
Research Capital
Research Capital
€4.77
Buy
245.42%
Upside
Reiterated
04/10/26
Is NervGenPharma still undervalued?Uddin said the pivotal study is expected to enroll about 150 patients at roughly 60 sites across the United States and Canada, with startup activity already underway and trial initiation still expected around mid-2026. He said enrollment could be completed in the second half of 2027, with topline data in the first half of 2028 and a potential NDA filing in the second half of 2028.
Maxim Group Analyst forecast on DE:9UA
Michael Okunewitch
Maxim Group
Maxim Group
€8.67→€10.4
Buy
653.65%
Upside
Assigned
04/09/26
NervGen Pharma price target raised to $12 from $10 at MaximNervGen Pharma price target raised to $12 from $10 at Maxim
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
ACRVAcrivon Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering NervGen Pharma

3 Months
Andre UddinResearch Capital
Success Rate
2/3 ratings generated profit
67%
Average Return
-3.90%
Copying Andre Uddin's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of -3.90% per trade.
1 Year
Justin KeywoodStifel Nicolaus
Success Rate
6/11 ratings generated profit
55%
Average Return
+6.96%
Copying Justin Keywood's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +6.96% per trade.
2 Years
Justin KeywoodStifel Nicolaus
Success Rate
1/11 ratings generated profit
9%
Average Return
-12.75%
Copying Justin Keywood's trades and holding each position for 2 Years would result in 9.09% of your transactions generating a profit, with an average return of -12.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

9UA Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
6
7
8
5
4
Buy
5
5
5
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
12
13
6
5
In the current month, 9UA has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 9UA average Analyst price target in the past 3 months is 8.96.
Each month's total comprises the sum of three months' worth of ratings.

9UA Financial Forecast

9UA Earnings Forecast

Next quarter’s earnings estimate for 9UA is -€0.07 with a range of -€0.09 to -€0.04. The previous quarter’s EPS was -€0.23. 9UA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 9UA has Performed in-line its overall industry.
Next quarter’s earnings estimate for 9UA is -€0.07 with a range of -€0.09 to -€0.04. The previous quarter’s EPS was -€0.23. 9UA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 9UA has Performed in-line its overall industry.
No data currently available

9UA Sales Forecast

Next quarter’s sales forecast for 9UA is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were ―. 9UA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 9UA has Performed in-line its overall industry.
Next quarter’s sales forecast for 9UA is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were ―. 9UA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 9UA has Performed in-line its overall industry.

9UA Stock Forecast FAQ

What is DE:9UA’s average 12-month price target, according to analysts?
Based on analyst ratings, NervGen Pharma’s 12-month average price target is 8.96.
    What is DE:9UA’s upside potential, based on the analysts’ average price target?
    NervGen Pharma has 548.98% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NervGen Pharma a Buy, Sell or Hold?
          NervGen Pharma has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
            What is NervGen Pharma’s share price target?
            The average share price target for NervGen Pharma is 8.96. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €13.00 ,and the lowest forecast is €5.20. The average share price target represents 548.98% Increase from the current price of €1.38.
              What do analysts say about NervGen Pharma?
              NervGen Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of NervGen Pharma?
                To buy shares of DE:9UA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.